Director at Encompass Health (NYSE: EHC) adds shares via fee deferral

Rhea-AI Filing Summary

Encompass Health Corp director Christopher R. Reidy reported routine share acquisitions tied to director compensation arrangements. On January 15, 2026, he received 19 shares of Encompass Health common stock valued at $0 per share through an award of restricted stock units connected to a $0.19-per-share dividend. On the same date, he acquired an additional 346 shares at a weighted average price of $103.07 per share through the company’s Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to purchase stock in the market. Following these transactions, Reidy directly beneficially owned 15,450 shares of Encompass Health common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Reidy Christopher R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Encompass Health Common Stock	19	$0.00	--
Grant/Award	Encompass Health Common Stock	346	$103.07	$36K

Holdings After Transaction: Encompass Health Common Stock — 15,104 shares (Direct)

Footnotes (1)

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.79 to $103.08, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reidy Christopher R

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	01/15/2026		A		19(1)	A	$0	15,104	D
Encompass Health Common Stock	01/15/2026		A		346(2)	A	$103.07(3)	15,450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2026, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $102.80. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2025 to defer fixed percentages of their director fees for 2026. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on January 15, 2026.

3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $102.79 to $103.08, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

	/s/ Patrick Darby, attorney-in-fact for Christopher R. Reidy	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Encompass Health (EHC) report for Christopher R. Reidy?

Christopher R. Reidy, a director of Encompass Health Corp, reported acquiring Encompass Health common stock on January 15, 2026, through a dividend-linked restricted stock unit award and purchases under the Directors Deferred Stock Investment Plan.

How many Encompass Health (EHC) shares did the director acquire in this Form 4 filing?

The director acquired 19 shares through an award tied to restricted stock units and 346 shares through the Directors Deferred Stock Investment Plan, for a total of 365 shares reported on that date.

What price did the Encompass Health (EHC) director pay for the newly acquired shares?

The 19 shares related to restricted stock units were valued at $0 per share. The 346 shares purchased under the deferred fee plan carried a weighted average price of $103.07 per share, based on trades between $102.79 and $103.08.

What is the Encompass Health (EHC) Directors Deferred Stock Investment Plan mentioned in the filing?

The Directors Deferred Stock Investment Plan is a non-qualified deferral plan that allows non-employee directors to defer fixed percentages of their fees. Deferred fees are used by a plan administrator to purchase Encompass Health common stock in the market, and the stock is entitled to cash dividends that are reinvested in additional shares.

How are restricted stock units (RSUs) used for Encompass Health (EHC) directors in this Form 4?

Under outstanding RSU award agreements, additional RSUs are credited to each non-employee director’s account in connection with common stock dividend payments. On January 15, 2026, a $0.19-per-share dividend and a closing price of $102.80 determined the number of RSUs awarded.

How many Encompass Health (EHC) shares does the director own after these transactions?

After the reported transactions, Christopher R. Reidy directly beneficially owned 15,450 shares of Encompass Health common stock.